Ling Yan
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Cardiac Fibrosis and Remodeling
- Chemotherapy-induced cardiotoxicity and mitigation
Papers in
-
- Signaling Pathways in Disease 8
- S100 Proteins and Annexins 5
- Protein Tyrosine Phosphatases 5
- PI3K/AKT/mTOR signaling in cancer 4
-
- Cardiac Fibrosis and Remodeling 17
- Co-authors
- Hongyang Wang (5 shared papers)Le‐Xing Yu (3 shared papers)Hongliang Li (21 shared papers)Zhou‐Yan Bian (20 shared papers)Zhi‐Gang She (16 shared papers)Qizhu Tang (13 shared papers)David R. Clemmons (6 shared papers)Laura A. Maile (5 shared papers)
- Journals
- Hypertension (6 papers)Journal of Cellular Biochemistry (5 papers)Arteriosclerosis Thrombosis and Vascular Biology (3 papers)Medicine (3 papers)PLoS ONE (3 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Ling Yan
146 papers receiving 3.8k citations
Ling Yan's Hit Papers
Peers
Comparison fields: 5 of 166
- Cancer Research 659
- Cardiology and Cardiovascular Medicine 659
- Immunology 580
- Molecular Biology 1.7k
- Clinical Biochemistry 163
Countries citing papers authored by Ling Yan
This map shows the geographic impact of Ling Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Yan more than expected).
Fields of papers citing papers by Ling Yan
This network shows the impact of papers produced by Ling Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Yan. The network helps show where Ling Yan may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling Yan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 163 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 235 | |
| 2 | Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death Hit paper breakdown → | 2021 | 226 |
| 3 | 2019 | 176 | |
| 4 | 2014 | 146 | |
| 5 | 2019 | 113 | |
| 6 | 2022 | 98 | |
| 7 | 2010 | 92 | |
| 8 | 2011 | 76 | |
| 9 | 2009 | 75 | |
| 10 | 2008 | 74 | |
| 11 | 2019 | 74 | |
| 12 | 2008 | 68 | |
| 13 | 2013 | 67 | |
| 14 | 2022 | 64 | |
| 15 | 2012 | 64 | |
| 16 | 2010 | 62 | |
| 17 | 2020 | 61 | |
| 18 | 2008 | 55 | |
| 19 | 2005 | 54 | |
| 20 | 2009 | 51 |
About Ling Yan
Ling Yan is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Oncology and Surgery, having authored 163 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cardiac Fibrosis and Remodeling (17 papers), Advanced Glycation End Products research (10 papers), Signaling Pathways in Disease (8 papers), S100 Proteins and Annexins (5 papers), Protein Tyrosine Phosphatases (5 papers), NF-κB Signaling Pathways (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). The work is most often cited by research in Cancer Research (659 citations), Cardiology and Cardiovascular Medicine (659 citations), Immunology (580 citations), Molecular Biology (1.7k citations) and Clinical Biochemistry (163 citations). Ling Yan has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Hongyang Wang, Le‐Xing Yu, Hongliang Li, Zhou‐Yan Bian, Zhi‐Gang She, Qizhu Tang, David R. Clemmons, Laura A. Maile, Qi‐Zhu Tang and Feng Cao. Their work appears in journals such as Hypertension, Journal of Cellular Biochemistry, Arteriosclerosis Thrombosis and Vascular Biology, Medicine and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.